Clinical trials: Dysphagia, Esophageal
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
The purpose of this study was to assess the safety and effectiveness of once daily oral administration of dexlansoprazole delayed-release capsules in adolescent participants with symptomatic non-erosive gastroesophageal reflux…
- Trial name
- NCT01642602
- Testing
- Dexlansoprazole
- Where
- 64 sites in United States, Belgium and 6 more
- Volunteers
- 104 people
- Sponsor
- Takeda
Gastroesophageal Reflux
Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease
This is a remote study. No office visits required. The purpose and efficacy endpoint of this study is to assess whether GERD patients tolerate ISOT-101.
- Trial name
- NCT04491734
- Testing
- maltosyl-isomalto-oligosaccharides (MIMO)
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- ISOThrive Inc.
Mitral Valve Regurgitation
CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study
Clinical study to evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter Mitral Valve
- Trial name
- RELIEF (NCT02722551)
- Testing
- Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve
- Where
- 15 sites in Canada, Denmark and 5 more
- Sponsor
- Edwards Lifesciences
Erosive Esophagitis, GERD
Efficacy Study of Ilaprazole to Treat Erosive Esophgitis
This study compared Ilaprazole 20mg with lansoprazole 30mg for the healing of erosive esophagitis and resolution of heartburn.
- Trial name
- NCT01509261
- Testing
- Ilaprazole, Lansoprazole
- Where
- 19 sites in South Korea
- Volunteers
- 292 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Esophagitis, Gastro Oesophageal Reflux Disease
Clinical Investigation to Assess the Acid Neutralisation Activity of a Calcite Chewing Gum
This investigation is designed to evaluate the acid neutralisation action of a new test product versus unmatched placebo.
- Trial name
- NCT05129670
- Testing
- Calcite chewing gum
- Where
- Ireland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Healthcare (UK) Limited
Dysphagia
Phagenyx® Registry Study
A retrospective, open-label, matched-control registry study designed to characterize the effectiveness of Pharyngeal Electrical Stimulation (PES) to improve swallowing in patients with severe dysphagia post stroke when delivered…
- Trial name
- RESTORE-US (NCT06866418)
- Testing
- 1. Phagenyx® System Group Patients
- Where
- 3 sites in United States
- Volunteers
- 600 people
- Sponsor
- Phagenesis Ltd.
Gastroesophageal Reflux, Heartburn
Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.
The purpose of this study is to evaluate the effect of each of the rabeprazole treatment regimens on nocturnal heartburn symptoms.
- Trial name
- NCT00553449
- Testing
- rabeprazole
- Volunteers
- 48 people
- Sponsor
- Janssen-Ortho Inc., Canada
Barrett's Esophagus, GERD
Cytosponge Adequacy Study Evaluation II
This study will assess the Minimally Invasive Esophageal Cytology Collection System in Patients with Barrett's Esophagus or GERD Symptoms.
- Trial name
- CASEII (NCT02395471)
- Testing
- Cytosponge™ Cell Collection Device
- Where
- 5 sites in United States
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Gastroesophageal Reflux Disease
Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration…
- Trial name
- NCT05614752
- Testing
- Fexuprazan
- Where
- South Korea
- Volunteers
- 10,067 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Gastroesophageal Reflux Disease
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
The purpose of the study is to evaluate efficacy and safety of arbaclofen placarbil (XP19986) versus placebo as adjunctive therapy in subjects with troublesome GERD symptoms despite therapy with approved doses of a Proton Pump…
- Trial name
- NCT00978016
- Testing
- arbaclofen placarbil-Cohort 1, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3
- Where
- 64 sites in United States, Canada
- Volunteers
- 460 people
- Sponsor
- XenoPort, Inc.
Gastroesophageal Reflux
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
The purpose of this study is to determine whether Dexlansoprazole once daily (QD) is effective in treating patients with night heartburn.
- Trial name
- NCT00627016
- Testing
- Dexlansoprazole
- Where
- 43 sites in United States
- Volunteers
- 305 people
- Sponsor
- Takeda
Benign Esophageal Lesions
SX ELLA Esophageal Degradable BD Stent System
The SX-ELLA Stent Esophageal Degradable BD (BD Stent) is designed for dilation of benign esophageal lesions, namely: (1) stenosis (peptic, anastomotic or caustic) refractory to standard therapy, (2) achalasia refractory to…
- Trial name
- DESTINY (NCT01337206)
- Testing
- Stenting with ELLA Biodegradable stent, Standard Dilations
- Where
- 8 sites in Belgium, Italy and 3 more
- Volunteers
- 66 people
- Sponsor
- Cook Group Incorporated
Gastroesophageal Reflux Disease
Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets
It is planned to compare the efficacy and safety of rabeprazole 50 mg DDR (dual delayed release) capsules versus rabeprazole 20 mg enteric coated tablets administered once daily in patients with Gastroesophageal Reflux Disease…
- Trial name
- NCT03037606
- Testing
- Rabelis DDR 50 mg Capsules, Pariet 20 mg Enteric Coated Tablets
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Reflux, Heartburn
Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)
The aim of this project is to compare the GERD clinical outcomes in patients where a structured pathway using the GerdQ questionnaire is implemented compared with the clinical outcomes of those treated without this…
- Conditions
- Reflux, Heartburn, Regurgitation, Esophagitis
- Trial name
- NCT00842387
- Where
- 66 sites in Austria, Italy and 3 more
- Volunteers
- 2,370 people
- Sponsor
- AstraZeneca
GERD
Nexium RESPONSE Trial
The primary purpose of the study is to develop, and test, an algorithm for identification of responders to empirical esomeprazole treatment in general practices.
- Trial name
- NCT00318968
- Testing
- Esomeprazole
- Where
- 38 sites in Denmark
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD)
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
Study to assess the effects of adding tegaserod to PPI therapy results in clinically meaningful improvement of GERD symptoms in patients with incomplete relief of symptoms on daily PPI therapy alone.
- Trial name
- NCT00171418
- Testing
- Tegaserod
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis
Gastroesophageal Reflux Disease
Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn
The purpose of this study is to determine the long-term safety profile of daily treatment with dexlansoprazole MR in subjects with gastroesophageal reflux disease.
- Trial name
- NCT00255190
- Testing
- Dexlansoprazole MR
- Where
- 181 sites in United States
- Volunteers
- 591 people
- Sponsor
- Takeda
Polymyositis, Dermatomyositis
Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive to traditional immunosuppressive and/or…
- Trial name
- NCT01148810
- Testing
- BAF312
- Where
- 6 sites in United States, Czechia and 3 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Dysphagia, Non-Small Cell Lung Cancer
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if palifermin will reduce the incidence of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for treatment of unresectable stage III…
- Conditions
- Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer
- Trial name
- NCT00094861
- Testing
- Palifermin, Radiotherapy, Paclitaxel
- Volunteers
- 100 people
- Sponsor
- Swedish Orphan Biovitrum
Gastroesophageal Reflux
Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified…
- Trial name
- NCT00847808
- Testing
- Dexlansoprazole MR QD
- Where
- 52 sites in United States
- Volunteers
- 178 people
- Sponsor
- Takeda